Dec 05, 2012, 11.07 AM IST
The Supreme Court today reserved its order on Swiss pharma giant Novartis AG's plea for getting its blood cancer drug Glivec patented in India.
A bench of justices Aftab Alam and Ranajan Prakash Desai reserved its verdict after marathon arguments which went on for months.
Novartis approached the apex court challenging the order of Chennai-based Intellectual Property Appellate Board (IPAB), which rejected its appeal against patent department's decision on Glivec.
The Comptroller General of Patent and Design had denied patent to Glivec on several grounds including its alleged failure to meet stipulations under sections 3(d) and 3(b) of the Indian Patent Law.
Section 3(d) restricts patents for already known drugs unless the new claims are superior in terms of efficacy.
Section 3(b) restricts patents for products that are against public interest and do not demonstrate enhanced efficacy over existing products.
Novartis India stock price
On December 05, 2013, at 12:52 hrs Novartis India was quoting at Rs 440.00, up Rs 4.10, or 0.94 percent. The 52-week high of the share was Rs 690.00 and the 52-week low was Rs 361.00.
The company's trailing 12-month (TTM) EPS was at Rs 35.30 per share as per the quarter ended September 2013. The stock's price-to-earnings (P/E) ratio was 12.46. The latest book value of the company is Rs 281.66 per share. At current value, the price-to-book value of the company is 1.56.
Tags: Novartis, Intellectual Property Appellate Board, Glivec, Comptroller General of Patent and Design
Video of the day
Dec 5 2013, 12:20
- in FII View
Dec 4 2013, 11:08
- in FII View
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.